Galapagos and Gilead to end late-stage studies of lung disease drug – Reuters

Galapagos and Gilead to end late-stage studies of lung disease drug – Reuters

Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis, the companies said on Wednesday.

Read More…

You May Also Like